Data gathered: November 23
AI Stock Analysis - TG Therapeutics (TGTX)
Analysis generated November 3, 2024. Powered by Chat GPT.
TG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's lead products, ublituximab and umbralisib, form part of its core therapeutic pipeline targeting hematologic malignancies, multiple sclerosis, and other autoimmune disorders. TG Therapeutics aims to carve a niche in the market by developing therapies that offer efficacy and safety advantages over existing treatments.
Stock Alerts - TG Therapeutics (TGTX)
 |
TG Therapeutics | November 21 Price is up by 5.6% in the last 24h. |
|
TG Therapeutics | November 19 AI Score is down by 35.6% in the last couple of days. |
|
TG Therapeutics | November 15 AI Score is down by 25.4% in the last couple of days. |
|
TG Therapeutics | November 15 Price is down by -5.3% in the last 24h. |
Alternative Data for TG Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 44 | Sign up | Sign up | Sign up |
| Google Trends | 27 | Sign up | Sign up | Sign up |
| Patents | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 92 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,845 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,079 | Sign up | Sign up | Sign up |
| Twitter Mentions | 34 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 22 | Sign up | Sign up | Sign up |
| Linkedin Employees | 382 | Sign up | Sign up | Sign up |
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases.
| Price | $35.07 |
| Target Price | Sign up |
| Volume | 2,580,000 |
| Market Cap | $5.38B |
| Year Range | $13.32 - $35.07 |
| Dividend Yield | 0% |
| PE Ratio | 39.29 |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
KBC Group NV Acquires 1,092 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)November 22 - ETF Daily News |
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500November 21 - Finnhub |
|
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™November 21 - GlobeNewswire |
|
|
State of New Jersey Common Pension Fund D Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)November 18 - ETF Daily News |
|
Entropy Technologies LP Buys Shares of 31,200 TG Therapeutics, Inc. (NASDAQ:TGTX)November 15 - ETF Daily News |
 |
HC Wainwright Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) StockNovember 9 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 84M | 51M | 33M | 3.9M | 15M | 0.020 |
| Q2 '24 | 73M | 47M | 26M | 6.9M | 8.9M | 0.040 |
| Q1 '24 | 63M | 40M | 23M | -11M | -9.2M | -0.070 |
| Q4 '23 | 42M | 39M | 2.7M | -14M | -12M | -0.100 |
| Q3 '23 | 162M | 36M | 126M | 114M | 115M | 0.730 |
Insider Transactions View All
| Lonial Sagar filed to sell 100,195 shares at $30.4. November 12 '24 |
| Charney Laurence N filed to sell 212,479 shares at $30.2. November 12 '24 |
| Echelard Yann filed to sell 224,098 shares at $24.5. November 7 '24 |
| Lonial Sagar filed to sell 105,195 shares at $16.9. June 20 '24 |
| Lonial Sagar filed to sell 99,293 shares at $16.4. June 20 '24 |
Similar companies
Read more about TG Therapeutics (TGTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of TG Therapeutics?
The Market Cap of TG Therapeutics is $5.38B.
What is TG Therapeutics' PE Ratio?
As of today, TG Therapeutics' PE (Price to Earnings) ratio is 39.29.
What is the current stock price of TG Therapeutics?
Currently, the price of one share of TG Therapeutics stock is $35.07.
How can I analyze the TGTX stock price chart for investment decisions?
The TGTX stock price chart above provides a comprehensive visual representation of TG Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TG Therapeutics shares. Our platform offers an up-to-date TGTX stock price chart, along with technical data analysis and alternative data insights.
Does TGTX offer dividends to its shareholders?
As of our latest update, TG Therapeutics (TGTX) does not offer dividends to its shareholders. Investors interested in TG Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of TG Therapeutics?
Some of the similar stocks of TG Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.